This study investigates how the COVID-19 pandemic may have influenced the sales volumes of psoriasis medications in Germany. It involves an analysis of pharmacy data spanning from 2019 to 2021, assessing trends in the sales of first- and second-line biologic treatments. The research seeks to identify patterns across different age groups and regional variances in German states, particularly those with varying levels of COVID-19 incidence. The study also highlights the need for additional research to better understand the motivations and apprehensions of patients during this period.
Kahn, M., Papukchieva, S., Jacyshyn-Owen, E., Grimm, S., Eberl, M., Schneeweiss, S., Otten, M., Augustin, M. & Friedrich, B. (2023) The Impact of the COVID-19 Pandemic on Prescription Drug Use in Patients with Psoriasis Vulgaris in Germany. Springer Link, Dermatology and Therapy Volume 13, pages 2609–2620, (2023)
